Of 30 sufferers for whom FLIPI scores were available, 87 percent of patients were classified as either intermediate or risky, and 73 percent of patients experienced positive bone marrow involvement. Sufferers had been treated with 20 mg/time of lenalidomide on times 1-21 of a 28-day cycle and 375 mg/m2 of rituximab on day 1 of each cycle for 6 cycles. Related StoriesFDA approves LONSURF for treatment of patients with metastatic colorectal cancerResearchers determine new focus on for novel immune-oncology treatmentsNew guidance statement on palliative care to be offered at 2015 Palliative Care in Oncology SymposiumResults from the Phase II single-arm study reported that of 45 evaluable patients, the overall response rate was 89 percent , with 73 percent of patients achieving a total response .The individuals have been implanted with intracranial depth electrodes by Dr. Itzhak Fried, a UCLA professor of neurosurgery and psychiatry and a co-writer of the scholarly research, to recognize seizure foci for potential medical procedures. The positioning of electrodes was structured exclusively on clinical criteria. The experts, with the patients' consent, utilized these same electrodes to piggyback their research. A membrane equivalent to that utilized for kidney dialysis and an extremely sensitive radioimmunoassay process were used to gauge the launch of hypocretin and MCH.